Nevirapine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Nevirapine: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Nevirapine (DB00238) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) whose established clinical use is treatment of HIV-1 infection in humans. The TxGNN model's top-ranked prediction points to Feline Acquired Immunodeficiency Syndrome — a veterinary condition in cats caused by FIV, not a human disease — currently supported by 0 clinical trials and only 1 preclinical/mechanistic publication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 Infection (per literature evidence in this pack; not confirmed by Germany regulatory data — drug is not marketed) |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome (FIV infection in cats) |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L4 (single preclinical/in vitro mechanistic study, no clinical trials) |
| Germany Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for nevirapine is not available in this evidence pack (flagged as a High-severity data gap). Based on known information referenced in the supporting literature, nevirapine is a first-generation NNRTI that binds directly to HIV-1 reverse transcriptase, and its efficacy in HIV-1 infection is well established in clinical practice.
The predicted indication, feline acquired immunodeficiency syndrome, is caused by Feline Immunodeficiency Virus (FIV) — a lentivirus structurally and functionally related to HIV. The rationale for TxGNN's prediction is mechanistic proximity: both viruses rely on a reverse transcriptase enzyme for replication, and researchers have directly tested whether HIV-1-specific NNRTIs (nevirapine, efavirenz, rilpivirine) could cross-inhibit FIV reverse transcriptase.
However, an important caveat: this is a veterinary indication (cats), not a human disease. NNRTIs are known to be highly virus-specific due to differences in the reverse transcriptase binding pocket across lentivirus species (a limitation also documented for nevirapine against SIV/HIV-2 in the rank-2 prediction of this pack). No data in this pack demonstrates that nevirapine effectively inhibits FIV RT in vitro or in vivo — the cited study only investigated the potential of NNRTIs for this purpose. This prediction should therefore be treated as a low-confidence, non-human signal rather than a human drug repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38031646 | 2023 | Preclinical / in vitro biochemical-structural study | Journal of Veterinary Science | Compared nevirapine, efavirenz, and rilpivirine (HIV NNRTIs) against feline and human immunodeficiency virus reverse transcriptase to assess potential utility of NNRTIs for treating FIV-infected cats; no effective FIV treatment currently exists. |
Germany Market Information
Nevirapine is currently not marketed in Germany; no marketing authorization records are available in the evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA/BfArM label warnings and contraindications are recorded as a Blocking data gap (DG001) in this evidence pack, meaning this candidate cannot yet proceed to the S1 safety pre-assessment stage regardless of efficacy evidence.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction targets a veterinary disease (feline AIDS) rather than a human indication, and is supported by only a single preclinical/mechanistic publication with no clinical trials. This is further compounded by a Blocking-severity gap in TFDA/BfArM safety labeling data, which prevents any safety pre-assessment. Nevirapine's other TxGNN predictions in this pack (simian immunodeficiency virus infection — an animal research model; and a rare neurodevelopmental disorder with no supporting evidence at all) are similarly non-actionable for human repurposing, reinforcing a Hold across the candidate set.
To proceed, the following is needed:
- TFDA/BfArM package insert data (warnings, contraindications) to resolve the Blocking gap (DG001)
- Confirmed mechanism of action (MOA) and original approved human indication from DrugBank (DG002)
- Clarification of clinical relevance — the current top prediction is a non-human/veterinary condition and requires re-scoring against genuinely human disease targets
- If pursuing the FIV signal for translational/veterinary purposes only, in vitro efficacy data (IC50/binding affinity of nevirapine against FIV reverse transcriptase) beyond the single exploratory publication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.